https://ir.icecure-medical.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_54f40390b69697dace3343a57e47c1a7/icecuremedical/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.icecure-medical.com/news-events/press-releases/detail/240/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026 Tue, 13 Oct 26 08:05:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/240/icecure-highlights-clinical-data-and-strong-physician-engagement-for-prosense-breast-cancer-cryoablation-at-eusobi-2026 https://ir.icecure-medical.com/news-events/press-releases/detail/239/icecure-expands-prosense-choice-study-for-low-risk-breast-cancer-adding-legacy-health-in-portland-or-as-u-s-clinical-site Tue, 06 Oct 26 08:25:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/239/icecure-expands-prosense-choice-study-for-low-risk-breast-cancer-adding-legacy-health-in-portland-or-as-u-s-clinical-site https://ir.icecure-medical.com/news-events/press-releases/detail/238/icecure-medical-receives-regulatory-approval-to-market-prosense-in-china Thu, 10 Sep 26 07:58:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/238/icecure-medical-receives-regulatory-approval-to-market-prosense-in-china https://ir.icecure-medical.com/news-events/press-releases/detail/237/icecure-signs-exclusive-distribution-agreement-for-prosense-cryoablation-systems-in-the-netherlands Mon, 24 Aug 26 07:50:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/237/icecure-signs-exclusive-distribution-agreement-for-prosense-cryoablation-systems-in-the-netherlands https://ir.icecure-medical.com/news-events/press-releases/detail/236/west-cancer-center-receives-irb-approval-to-commence-icecures-choice-study-for-breast-cancer-cryoablation Thu, 20 Aug 26 08:10:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/236/west-cancer-center-receives-irb-approval-to-commence-icecures-choice-study-for-breast-cancer-cryoablation https://ir.icecure-medical.com/news-events/press-releases/detail/235/icecure-highlights-two-new-peer-reviewed-publications-supporting-cryoablation-in-breast-cancer-treatment-de-escalation Thu, 13 Aug 26 09:10:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/235/icecure-highlights-two-new-peer-reviewed-publications-supporting-cryoablation-in-breast-cancer-treatment-de-escalation https://ir.icecure-medical.com/news-events/press-releases/detail/234/icecure-reports-its-financial-results-for-the-first-half-of-2026-with-45-revenue-growth-year-over-year Wed, 12 Aug 26 08:30:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/234/icecure-reports-its-financial-results-for-the-first-half-of-2026-with-45-revenue-growth-year-over-year https://ir.icecure-medical.com/news-events/press-releases/detail/233/icecure-medical-adds-adventist-health-as-u-s-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer-cryoablation-treatment Thu, 06 Aug 26 08:05:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/233/icecure-medical-adds-adventist-health-as-u-s-clinical-site-for-its-post-marketing-choice-study-for-low-risk-breast-cancer-cryoablation-treatment https://ir.icecure-medical.com/news-events/press-releases/detail/232/icecure-medical-to-report-first-half-2026-financial-and-operating-results-on-august-12-2026 Wed, 05 Aug 26 08:30:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/232/icecure-medical-to-report-first-half-2026-financial-and-operating-results-on-august-12-2026 https://ir.icecure-medical.com/news-events/press-releases/detail/231/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-guidelines-citing-icecures-fda-clearance-of-prosense Wed, 29 Jul 26 08:25:00 -0400 https://ir.icecure-medical.com/news-events/press-releases/detail/231/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-guidelines-citing-icecures-fda-clearance-of-prosense